Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Turning Point Therapeutics Inc (TPTX)

Turning Point Therapeutics Inc (TPTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,821,180
  • Shares Outstanding, K 35,850
  • Annual Sales, $ 0 K
  • Annual Income, $ -24,785 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.21

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.67
  • Number of Estimates 4
  • High Estimate -0.63
  • Low Estimate -0.72
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
35.67 +46.12%
on 10/25/19
52.40 -0.52%
on 11/20/19
+15.23 (+41.27%)
since 10/18/19
3-Month
32.71 +59.37%
on 10/14/19
58.56 -10.98%
on 08/28/19
+6.21 (+13.52%)
since 08/20/19

Most Recent Stories

More News
Turning Point Therapeutics to Participate in Upcoming Investor Conferences

Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, announced that President and CEO Athena Countouriotis, M.D., will participate...

TPTX : 52.13 (+2.62%)
Turning Point Therapeutics Initiates Phase 1/2 Clinical Study of Repotrectinib in Pediatric Patients

Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today announced initiation of a Phase 1/2 clinical study of its lead...

TPTX : 52.13 (+2.62%)
Turning Point Therapeutics Initiates Phase 1/2 Clinical Study of TPX-0046, a Novel RET/SRC Inhibitor

Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today announced initiation of a Phase 1/2 clinical study of its drug...

TPTX : 52.13 (+2.62%)
The Zacks Analyst Blog Highlights: Zoom Video Communications, Beyond Meat, Turning Point Therapeutics and Cortexyme

The Zacks Analyst Blog Highlights: Zoom Video Communications, Beyond Meat, Turning Point Therapeutics and Cortexyme

CRTX : 25.61 (+3.18%)
ZM : 70.99 (+1.94%)
BYND : 78.12 (+1.00%)
TPTX : 52.13 (+2.62%)
4 Best-Performing IPOs So Far in 2019

Companies that went public this year and did well in terms of price performance did so on the back of solid financials, positive cash flows and growing revenues.

AMZN : 1,745.53 (-0.41%)
FB : 197.51 (-0.91%)
CRTX : 25.61 (+3.18%)
TPTX : 52.13 (+2.62%)
BYND : 78.12 (+1.00%)
LYFT : 43.95 (-0.45%)
UBER : 28.03 (+3.62%)
PINS : 19.40 (-1.42%)
ZM : 70.99 (+1.94%)
WORK : 21.70 (+2.46%)
Turning Point Therapeutics: 3Q Earnings Snapshot

SAN DIEGO (AP) _ Turning Point Therapeutics Inc. (TPTX) on Monday reported a loss of $20.5 million in its third quarter.

TPTX : 52.13 (+2.62%)
Turning Point Therapeutics Reports Third Quarter 2019 Financial and Operational Results

-- Registrational Phase 2 Study of Repotrectinib Ongoing

TPTX : 52.13 (+2.62%)
Turning Point Therapeutics to Host Third Quarter 2019 Conference Call

Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, will report third quarter financial results following the close of...

TPTX : 52.13 (+2.62%)
Turning Point Therapeutics Announces FDA Clearance of Investigational New Drug Application for TPX-0046, a Novel RET/SRC Inhibitor

Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today announced clearance by the U.S. Food and Drug Administration...

TPTX : 52.13 (+2.62%)
Turning Point Therapeutics Announces Pricing of Public Offering of Common Stock

Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today announced the pricing of its public offering of 4,500,000 shares...

TPTX : 52.13 (+2.62%)
Trade TPTX with:

Business Summary

Turning Point Therapeutics is a clinical-stage biopharmaceutical company designing and developing novel small molecule, targeted oncology therapies to address key limitations of existing therapies and improve the lives of patients. Their internally developed and wholly owned pipeline of next-generation...

See More

Key Turning Points

2nd Resistance Point 53.81
1st Resistance Point 52.97
Last Price 52.13
1st Support Level 50.72
2nd Support Level 49.32

See More

52-Week High 58.56
Last Price 52.13
Fibonacci 61.8% 45.44
Fibonacci 50% 41.39
Fibonacci 38.2% 37.33
52-Week Low 24.21

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar